The disclosure relates to a phosphorus-containing group-substituted quinoline compound of formula (I) wherein the variables are as defined in the specification. The preparation process and application of the compound, and pharmaceutical formulation comprising phosphorus substituted group-containing quinoline-like compound are also disclosed. These phosphorus-containing group-substituted quinoline compounds are protein kinase inhibitor and can be used for treating protein kinase abnormal activity-associated diseases, such as neoplasm, cancer, psoriasis, hepatic cirrhosis, diabetes, angiogenesis-mediated diseases, eye diseases, immune system diseases, or cardiovascular diseases.
